<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifteen patients ranging in age from 1-29 years (median age 9 years) had bone marrow transplantations (BMT) from related donors other than HLA mixed lymphocyte culture (MLC) identical siblings </plain></SENT>
<SENT sid="1" pm="."><plain>Donors were selected on the basis of HLA similarity and low reactivity in the MLC </plain></SENT>
<SENT sid="2" pm="."><plain>Posttransplant immunosuppression consisting of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX), antithymocyte globulin (ATG), and <z:chebi fb="0" ids="8382">prednisone</z:chebi> was used in an effort to decrease <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="3" pm="."><plain>Seven children were treated for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 7 for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e>, and 1 for <z:hpo ids='HP_0011002'>osteopetrosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Primary engraftment failure contributed to <z:hpo ids='HP_0011420'>death</z:hpo> in 3 patients, <z:hpo ids='HP_0000001'>all</z:hpo> of whom had <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Nine of 12 engrafted patients developed moderate-to-severe <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Of the 15 patients, 7 developed <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients demonstrated mixed chimerism (at or beyond 3 months posttransplant) </plain></SENT>
<SENT sid="8" pm="."><plain>Two of the seven patients treated for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> are currently alive six months and more than five years posttransplant; the latter patient has <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="9" pm="."><plain>Four of the seven patients treated for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> are currently alive more than 500 days posttransplantation </plain></SENT>
<SENT sid="10" pm="."><plain>Three have <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="11" pm="."><plain>Analysis of patient outcome according to the degree of similarity in histocompatibility testing revealed that patients with low reactivity in the MLC (less than 5% relative response in both directions) had a better prognosis (5/6, 83% long-term survival) than patients with maximum donor vs. recipient mixed lymphocyte culture relative response greater than 5% (1/9, 12% long-term survival), P = .016 </plain></SENT>
</text></document>